ZFIN ID: ZDB-FISH-150901-212
Fish name: twu34Tg
Genotype: twu34Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by twu34Tg
Human Disease Conditions Citations
congestive heart failure chemical treatment by environment: Terfenadine Quan et al., 2020
dilated cardiomyopathy chemical treatment by environment: Terfenadine Gu et al., 2017
GENE EXPRESSION
Gene expression in twu34Tg
RNA expression
Expressed Gene Structure Conditions Figures
alcama standard conditions Fig. 1,  Fig. S1,  Fig. S3,  Fig. S4 from Rohr et al., 2008
aqp8a.1 standard conditions Fig. 3 with image from Koun et al., 2016
atp1a1a.1 standard conditions Fig. 4 with image from Langenbacher et al., 2012
atp2a2a control Fig. 5 from Shi et al., 2020
bmp4 standard conditions Fig. 1 with image from Veerkamp et al., 2013
ctnna1 standard conditions Fig. 5 with image from Rohr et al., 2006
fabp2 standard conditions Figure 1 with image from Lu et al., 2020
fn1a standard conditions Fig. 3 with image,  Fig. S1 with image from Langenbacher et al., 2012
Fig. 2,  Fig. 3 from Trinh et al., 2005
fn1b control Fig. 4 with image from Steed et al., 2016
fntb control Fig. 1 from Aguirre et al., 2014
foxa3 standard conditions Fig. 2 from Wang et al., 2017
foxj1a standard conditions Fig. S1 from Stubbs et al., 2008
gna13b standard conditions Fig. 4 with image from Ye et al., 2013
has2 control Fig. 4 with image from Steed et al., 2016
heg1 standard conditions Figure 1 with image from Lu et al., 2020
il1b control Fig. 1,  Fig. 2 from Shi et al., 2017
chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
klf2a control Fig. 4 with image from Steed et al., 2016
myh6 standard conditions Figure 1 with image from Lu et al., 2020
Fig. 6 from Kim et al., 2015
myh7 control Fig. 3 from Shi et al., 2020
Fig. 6 from Kim et al., 2015
myl7 control Fig. 3 from Shi et al., 2020
Fig. 6 from Kim et al., 2015
ndufa7 standard conditions Figure 2 with image from Shi et al., 2020
nkx2.5 standard conditions Fig. 2 from Wang et al., 2017
nppa control Fig. 5 from Shi et al., 2020
Fig. 1 from Shi et al., 2017
chemical treatment: tacrolimus (anhydrous) Fig. 5 from Shi et al., 2020
Fig. 1 from Shi et al., 2017
nppb standard conditions Fig. 5 from Shi et al., 2020
Fig. 6 from Gu et al., 2017
Fig. 1 from Shi et al., 2017
chemical treatment: tacrolimus (anhydrous) Fig. 5 from Shi et al., 2020
Fig. 1 from Shi et al., 2017
pals1a standard conditions Fig. 5 from Bit-Avragim et al., 2008
ppp3r1a control Fig. 5 from Shi et al., 2020
ptgs2b control Fig. 1,  Fig. 2 from Shi et al., 2017
chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
s1pr2 standard conditions Fig. 4 with image from Ye et al., 2013
smarca5 control Fig. 1 from Aguirre et al., 2014
tjp1a standard conditions Fig. 4 with image,  Fig. 5 with image from Rohr et al., 2006
Fig. 1,  Fig. 3 from Trinh et al., 2005
xirp1 standard conditions Fig. 3 with image from Otten et al., 2012
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab-S46 standard conditions Fig. 3 from Bit-Avragim et al., 2008
Fig. 4 from Lange et al., 2008
Fig. S4 from Rohr et al., 2008
Ab2-isl chemical treatment by environment: ethanol Fig. 4 with image from Sarmah et al., 2017
Ab1-ctnnb control Fig. 3 with image from Rydeen et al., 2016
zn-8 standard conditions Fig. 4,  Fig. 6 from Li et al., 2014
Fig. 5 with image from Wythe et al., 2011
Ab2-fn control Fig. 3 with image from Qiao et al., 2014
Ab1-smad standard conditions Fig. 3 with image from Lenhart et al., 2013
Ab4-atp2a2 control Fig. 5 from Shi et al., 2020
Ab2-isl standard conditions Fig. 4 with image from Sarmah et al., 2017
Fig. 2 with image from Tessadori et al., 2012
Ab1-tjp1 standard conditions Fig. 3 with image from Rydeen et al., 2016
Fig. 5 from Bit-Avragim et al., 2008
Ab1-tuba control Fig. 1 from Stubbs et al., 2008
Ab1-prkcz standard conditions Fig. 3 with image from Arrington et al., 2009
zn-5 alcama standard conditions Fig. 1,  Fig. S1,  Fig. S3,  Fig. S4 from Rohr et al., 2008
Ab3-atp1a1 atp1a1a.1 standard conditions Fig. 4 with image from Langenbacher et al., 2012
AB9-GFP EGFP standard conditions Fig. 3 with image from Arrington et al., 2009
Ab1-pals1a pals1a standard conditions Fig. 5 from Bit-Avragim et al., 2008
Ab1-xirp1 xirp1 standard conditions Fig. 3 with image from Otten et al., 2012
PHENOTYPE
Phenotype in twu34Tg
Phenotype Conditions Figures
atrioventricular canal elongated, abnormal chemical treatment by environment: tolterodine Fig. 7 from Burczyk et al., 2019
atrioventricular canal development process quality, abnormal organ culture: heart, chemical treatment: (S)-blebbistatin Fig. 5 from Noël et al., 2013
atrioventricular canal development process quality, abnormal chemical treatment: cytochalasin B, organ culture: heart Fig. 5 from Noël et al., 2013
atrium increased size, abnormal chemical treatment by environment: Terfenadine Fig. 3 with image from Gu et al., 2017
cardiac muscle cell apoptotic, abnormal chemical treatment by environment: Terfenadine Fig. 5 with image from Gu et al., 2017
cardiac muscle cell decreased amount, abnormal control Fig. 1 with image from Lu et al., 2017
cardiac muscle cell decreased amount, abnormal chemical treatment by environment: ethanol Fig. 2 with image from Sarmah et al., 2017
cardiac ventricle decreased size, abnormal chemical treatment by environment: tolterodine Fig. 7 from Burczyk et al., 2019
cardiac ventricle increased volume, abnormal chemical treatment by environment: isoprenaline Fig. 2 from Kossack et al., 2017
cardiac ventricle morphology, abnormal chemical treatment by environment: tolterodine Fig. 7 from Burczyk et al., 2019
embryonic heart tube left/right pattern formation process quality, abnormal chemical treatment: SB 505124 Fig. 1 with image from Lenhart et al., 2013
heart ptgs2b expression amount, ameliorated chemical treatment by environment: aristolochic acid A, chemical treatment by environment: empagliflozin Fig. 1 from Shi et al., 2017
heart nppa expression amount, ameliorated chemical treatment by environment: aristolochic acid A, chemical treatment by environment: empagliflozin Fig. 1 from Shi et al., 2017
heart il1b expression amount, ameliorated chemical treatment by environment: aristolochic acid A, chemical treatment by environment: empagliflozin Fig. 1 from Shi et al., 2017
heart nppb expression amount, ameliorated chemical treatment by environment: aristolochic acid A, chemical treatment by environment: empagliflozin Fig. 1 from Shi et al., 2017
heart edematous, abnormal chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
heart hypoplastic, abnormal control Fig. 1 with image from Lu et al., 2017
heart nppb expression increased amount, abnormal chemical treatment by environment: aristolochic acid A Fig. 1 from Shi et al., 2017
heart nppa expression increased amount, abnormal chemical treatment by environment: aristolochic acid A Fig. 1 from Shi et al., 2017
heart il1b expression increased amount, abnormal chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
heart ptgs2b expression increased amount, abnormal chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
heart morphology, abnormal chemical treatment by environment: isoniazide Fig. 2 with image from Ni et al., 2020
heart morphology, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Li et al., 2016
heart morphology, abnormal chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
heart morphology, ameliorated chemical treatment: valproic acid, chemical treatment: folic acid Fig. 4 from Yu et al., 2016
heart morphology, ameliorated chemical treatment by environment: aristolochic acid A, chemical treatment by environment: empagliflozin Fig. 1 from Shi et al., 2017
heart morphology, normal standard conditions Fig. 1 from Chi et al., 2008
heart straight, abnormal control Fig. 1 with image from Lu et al., 2017
heart volume, abnormal hypoxia Fig. 1,  Fig. 3 from Zou et al., 2019
heart volume, ameliorated oxygen content, hypoxia Fig. 3 from Zou et al., 2019
heart contraction arrhythmic, abnormal chemical treatment by environment: Terfenadine Fig. 3 with image from Gu et al., 2017
heart contraction decreased frequency, abnormal hypoxia Fig. 1,  Fig. 3 from Zou et al., 2019
heart contraction decreased frequency, ameliorated oxygen content, hypoxia Fig. 3 from Zou et al., 2019
heart contraction irregular rhythm, abnormal chemical treatment by environment: Terfenadine Fig. 3 from Quan et al., 2020
heart contraction rate, ameliorated chemical treatment by environment: aristolochic acid A, chemical treatment by environment: empagliflozin Fig. 1 from Shi et al., 2017
heart contraction rhythm quality, ameliorated chemical treatment by environment: fimasartan, chemical treatment by environment: Terfenadine Fig. 3 from Quan et al., 2020
heart looping arrested, abnormal chemical treatment: pharmaceutical Fig. 1 from Chen et al., 2012
heart looping disrupted, abnormal chemical treatment by environment: aristolochic acid A Fig. 1,  Fig. 2 from Shi et al., 2017
heart looping process quality, abnormal organ culture: heart, chemical treatment: (S)-blebbistatin Fig. 5 from Noël et al., 2013
heart looping process quality, abnormal chemical treatment: cytochalasin B, organ culture: heart Fig. 5 from Noël et al., 2013
heart looping process quality, normal chemical treatment: nocodazole, organ culture: heart Fig. 5 from Noël et al., 2013
heart rudiment morphology, normal standard conditions Fig. 1 with image from Holtzman et al., 2007
heart rudiment cardioblast anterior-lateral migration process quality, abnormal chemical treatment: SB 505124 Fig. 1 with image from Lenhart et al., 2013
heart tube decreased size, abnormal control Fig. 1 with image from Lu et al., 2017
myocardium apoptotic process increased occurrence, abnormal chemical treatment by environment: Terfenadine Fig. 5 with image from Gu et al., 2017
pericardium edematous, abnormal chemical treatment by environment: ethanol Fig. 1 with image from Li et al., 2016
whole organism nppb expression increased amount, abnormal standard conditions Fig. 6 from Gu et al., 2017
yolk syncytial layer edematous, abnormal chemical treatment by environment: isoniazide Fig. 2 with image from Ni et al., 2020

CITATIONS  (160)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.